[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640438":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":34,"centralContacts":39,"locations":44,"responsibleParty":58,"collaborators":29,"id":60,"slug":29,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":29,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":29,"enrollmentInfo":68,"targetDuration":29,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":47,"whyStopped":29,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"BeOne Medicines","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1a: Part A: Dose escalation, BG-75202 monotherapy","EXPERIMENTAL","Sequential cohorts of increasing dose levels of BG-75202 will be evaluated as monotherapy.",[13],"Drug: BG-75202",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase 1a: Part B: Dose escalation, BG-75202 + Hypomethylation Agent (HMA)","Sequential cohorts of increasing dose levels of BG-75202 in combination with Hypomethylation Agent (HMA) will be evaluated.",[13,18],"Drug: Hypomethylation Agent (HMA)",{"label":20,"type":10,"description":21,"interventionNames":22},"Phase 1b: Dose optimization, BG-75202 monotherapy","Participants will receive BG-75202 monotherapy",[13],[24,30],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","BG-75202","Administered orally",[9,15,20],null,{"type":25,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Hypomethylation Agent (HMA)","Administered Intravenous (IV) or Subcutaneous (SC)",[15],[35],{"name":36,"affiliation":37,"role":38},"Study Director","BeOne Medicine","STUDY_DIRECTOR",[40],{"name":36,"role":41,"phone":42,"phoneExt":29,"email":43},"CONTACT","877-828-5568","clinicaltrials@beonemed.com",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":29},"Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch","RECRUITING","Tianjin","Tianjin Municipality","301617","China",{"type":53,"coordinates":54},"Point",[55,56],117.17667,39.14222,{"lat":56,"lon":55},{"type":59,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100640438",false,"NCT07619287","An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies","A Phase 1a\u002F1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BG-75202, Alone and in Combination With Other Agents, in Patients With Myeloid Malignancies","Inclusion Criteria:\n\n* Patients must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), inclusive, at the time of signing the Informed consent form (ICF).\n* Patients must have a confirmed diagnosis of myeloid malignancies based on 2016 World Health Organization criteria, and meet the following categories:\n\n  * Relapsed\u002Frefractory; myeloid malignancies after ≥1 prior systemic therapy, per ELN; 2022 criteria; patients with actionable genetic alteration must have previously received targeted therapies unless contraindicated, unavailable\u002Finaccessible, or declined by patient.\n* Patients must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.\n\nExclusion Criteria:\n\n* Prior exposure to KAT6A\u002FB inhibitors\u002Fdegraders.\n* A diagnosis of acute promyelocytic leukemia or BCR-ABL-positive leukemia.\n* Known central nervous system involvement by leukemia\n* Use of antileukemic therapies without sufficient washout period\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.","ALL","18 Years",{"count":69,"type":70},118,"ESTIMATED","INTERVENTIONAL",[73],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A\u002FB inhibitor) alone and in combination with other agents in patients with myeloid malignancies.",[76],"Myeloid Malignancy",[78],"KAT6 inhibitor","2026-06-26",{"date":81,"type":82},"2026-06-30","ACTUAL",{"date":84,"type":82},"2026-06-23",{"date":86,"type":70},"2028-09-30",{"name":5,"class":6},1]